Reza safaei
Head of Medical Affairs
Pharmaceutical technology
RADUGA-3-Co-operative
New Zealand
Biography
Dr. Reza Safaei, M.D. has been Head of Medical Affairs at Nordic Nanovector ASA since August 2, 2017. Dr. Safaei brings extensive experience in the development and commercialization of novel therapeutics for hematological and solid cancers, gained with several world-leading biopharmaceutical companies. In his most recent role, Dr. Safaei held the position of Head of Medical Affairs Europe at Seattle Genetics, where he managed medical affairs and clinical development activities of pipeline products in acute myeloid leukemia and diffuse large B cell lymphoma (DLBCL), bladder cancer and advanced breast cancer. Prior to this, Dr. Safaei served as Director, Medical Development, Immuno-Oncology and Scientific Communications, Hematology at AMGEN Europe. Dr. Safaei is trained in Internal Medicine and holds a Medical Degree from the University of Goettingen, Germany.
Research Interest
Nanomedicine Design of Nanodrugs Personalized Nanomedicine Nanomaterials for drug delivery
